Deal-Making

Chinese CMC: CMAB to make bi-functional antibody for BJ

BJ Bioscience has contracted CMAB Biopharma to provide research, development and manufacturing services for a candidate therapeutic antibody called BJ-005. Under the deal, CMAB will conduct CMC development and manufacturing to support the planned submission of an IND for the candidate drug in China and the US. No further details about BJ-005 were provided. According to BJ Biosciences’ website the drug is a bi-functional antibody intended for the treatment of “cancer.” On the firm’s pipeline page the timing for IND…

Danaher offloads assets to Sartorius for $750m; GE buy pushed back to 2020

Sartorius will add biomolecular characterization, chromatography hardware and resins, and microcarriers in the deal, dependent on the closure of Danaher’s acquisition of GE Healthcare’s Biopharma business. Earlier this year, Danaher Corporation announced its intention to increase its presence in the bioprocessing space through the full biopharma portion of GE Healthcare’s Life Sciences business for approximately $21.4 billion (€19.2 billion). The GE business unit will, once the deal closes, become the latest subsidiary of Danaher, which boasts Pall Corporation, Sciex, and…

Combigene teams with Cobra and NBR on epilepsy gene therapy

Cobra Biologics will produce the AAV viral vector for Combigene’s epilepsy gene therapy from its facilities in Keele, UK. Nordic gene therapy company Combigene’s CG01 candidate is based on an adeno-associated viral vector (AAV) which administers a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where epileptic seizures begin. The project has received funding from the European Union’s Horizon 2020 research and innovation program and the manufacturing process was developed at the…

Big M&A: Alexion in $930m Achillion buy, UCB bids $2.1bn for Ra

In a big week for Big Pharma M&A, Alexion has agreed to buy Factor D inhibitor developer Achillion and UCB will add a late-stage FcRn targeting antibody through its acquisition of Ra Pharmaceuticals. Alexion Pharmaceuticals, which itself has been in the news recently as a potential target for M&A-hungry Amgen, announced today it has agreed to buy clinical-stage biopharmaceutical company Achillion Pharmaceuticals for approximately $930 million (€842 million). The deal adds oral small molecule Factor D inhibitors to treat people…

CDMO focus: Strategic gene therapy deals and $250m sell-off

Lonza strengthens gene therapy partnership with Prevail; Paragon and Brammer evolving form hyperstacks over to iCELLis units for Sarepta; Mallinckrodt sells off Biovectra. Welcome to Bioprocess Insider’s CDMO round-up. First up in this contract development and manufacturing organization (CDMO) round-up is Swiss firm Lonza, which is upping its partnership with Prevail Therapeutics. Lonza has worked on the process development of Prevail’s two lead gene therapy programs since 2018 and will now take the partnership to the next stage, using a…

Cellectis selects Lonza for off-the-shelf CAR-T manufacture

CDMO Lonza will make clinical batches of an allogeneic CAR-T cell candidate from its facility in the Netherlands for French firm Cellectis. Cellectis has a range of ‘UCART’ off-the-shelf chimeric antigen receptor (CAR) T-cell therapies in development for hematological malignancies, based on its TALEN gene-editing technology. To support this, the French biopharma has selected Swiss contract development and manufacturing organization (CDMO) Lonza to supply clinical materials from its facility in Geleen, added to its cell and gene therapy network through…

BWB startup pitch: Biopharm America’s got talent

Secure health data services firm Bowhead Health has won a startup pitch competition run jointly by the Xcelerate and Biopharm America conferences. Bioprocess Insider brought live commentary of the event at Biotech Week Boston. Presided over by seasoned journalist Mike Ward from the EBD Group, twelve participants – well, eleven as one didn’t show – pitched their startup healthcare focused companies in four-minute slots on stage at Biotech Week Boston. Last week’s event, a collaboration between Xconomy’s Xcelerate conference and…

Lundbeck adding migraine ‘blockbuster’ and Ab capabilities in $2bn Alder buy

Danish biopharma Lundbeck says it expects to launch the potential blockbuster migraine biologic eptinezumab early next year after agreeing to buy Alder BioPharmaceuticals. The cash deal, expected to close in Q4 2019, is worth $1.95 billion (€1.78 billion) and falls into Lundbeck’s “expand and invest growth strategy” announced by the Danish biopharma firm in February 2019, aimed at expnding its breadth in brain disease therapies and rebuilding its pipeline. Since then the firm acquired Abide Therapeutics, adding a serine hydrolases…

Lonza to make ‘NET’ antibody for Citryll

Citryll BV has partnered with CDMO Lonza to help develop and supply final drug product for its Neutrophil Extracellular Trap (NET) biology targeting antibody candidate. Under terms of the deal, financials of which have not been divulged, Swiss contract development and manufacturing organization (CDMO) Lonza will provide Dutch biotech firm Citryll in silico preclinical services used to assess manufacturability and immunogenicity, and final drug product in finished format for clinical material. Citryll’s candidate CIT-013 is a tACPA therapeutic antibody targeting…

MilliporeSigma buys data platform to bolster its Biopharma 4.0 offering

MilliporeSigma has bought the rights to the ProcessPad platform from Simplyfeye Softwares, adding the latest “building block” to its BioContinuum Platform. The ProcessPad platform from Simplyfeye Softwares Private Limited brings MilliporeSigma a data management and analytics solution capable of capturing development, scale-up, commercial and process data on a single platform as well as analyzing quantitative and qualitative batch manufacturing data. Financial details around the acquisition were not disclosed, but Michael Felo, director of Integrated Solutions Marketing, BioContinuum Platform, at MilliporeSigma,…